Zacks upgraded Adicet Bio to a Rank #2 (Buy), signaling increased analyst optimism about the company’s earnings prospects. The upgrade could push ACET shares higher in the near term—often on the order of 1–3% for similar biotech analyst upgrades. No new company financials or guidance were provided.
Zacks upgraded Adicet Bio to a Rank #2 (Buy), signaling increased analyst optimism about the company’s earnings prospects. The upgrade could push ACET shares higher in the near term—often on the order of 1–3% for similar biotech analyst upgrades. No new company financials or guidance were provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
